Loading
A phase 2 trial of tislelizumab in colorectal cancer, run by The First Affiliated Hospital of Zhengzhou University, not yet recruiting.
A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI. is a phase 2, interventional study registered as NCT05231850 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 70 participants, started 2022-03-01 and due to reach its primary completion in 2023-09-01. Interventions recorded: Tislelizumab. Conditions listed: Colon Cancer. Primary outcome: Primary End point: Disease Free survival [ Time Frame: 3 years ]. Colorectal eligibility wording from the registry: ", any T, N1 or N2, M0) adenocarcinoma of the colon (as defined by the presence of the inferior pole of the tumour above the peritoneal reflection - that is, at least 15 cm from the anal margin)". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tislelizumab, Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tislelizumab, Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tislelizumab, Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/